The present invention relates to a novel use of the active ingredient Pidotimod or its stereoisomers and/or physiologically acceptable salts thereof to treat inflammation associated diseases characterized by an aberrant hyperactivation of the non canonical NFkB pathway such as allergic diseases autoimmune diseases or other inflammatory diseases based on mechanisms different from allergic or autoimmune.